Philip Greenberg

Last updated

Philip Greenberg
NationalityAmerican
Education
Known for T cell receptor T cell therapy
Scientific career
Fields Hematology
Institutions
Website Fred Hutch page

Philip Greenberg is a professor of medicine, oncology, and immunology at the University of Washington and head of program in immunology at the Fred Hutchinson Cancer Research Center. His research is centered around T cell biology and therapeutic cell therapies. [1] He is a co-founder of Juno Therapeutics. [2] [3] [4]

Contents

Education and research

Greenberg graduated from Washington University in St. Louis with a degree in biology; he received his M.D. in 1971 from SUNY Downstate Medical Center. After completing postdoctoral training at the University of California at San Diego, he joined the Fred Hutchinson Cancer Center and the Division of Oncology at the University of Washington, in 1976. [5] His research is focused on T cell adoptive immunotherapy. His group has demonstrated the potential of isolating antigen-specific T cells and growing them to perform in vivo activity against a disease. [6] [7] [8] He has also done work on re-engineering T cells to produce TCR-T that will work for non-leukemia malignancies. [9]

Awards and honors

Related Research Articles

<span class="mw-page-title-main">E. Donnall Thomas</span> American hematologist

Edward Donnall "Don" Thomas was an American physician, professor emeritus at the University of Washington, and director emeritus of the clinical research division at the Fred Hutchinson Cancer Research Center. In 1990 he shared the Nobel Prize in Physiology or Medicine with Joseph E. Murray for the development of cell and organ transplantation. Thomas and his wife and research partner Dottie Thomas developed bone marrow transplantation as a treatment for leukemia.

The Society for Immunotherapy of Cancer (SITC), previously known as the International Society for Biological Therapy of Cancer (iSBTc), is a professional society of scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving outcomes in patients with cancer by advancing the science and application of cancer immunotherapy. Currently, SITC has more than 2,400 members, representing 22 medical specialties from 42 countries around the world, who are engaged in the research and treatment of cancer.

<span class="mw-page-title-main">Seattle Cancer Care Alliance</span> Cancer treatment and research center in Seattle, U.S.

Seattle Cancer Care Alliance (SCCA) is a cancer treatment and research center in Seattle, Washington. Established in 1998, this nonprofit provides clinical oncology care for patients treated at its three partner organizations: Fred Hutchinson Cancer Research Center, Seattle Children's and UW Medicine. Together, these four institutions form the Fred Hutch/University of Washington Cancer Consortium.

Owen Witte is an American physician-scientist at the University of California, Los Angeles. He is a University Professor of microbiology, immunology and molecular genetics in the David Geffen School of Medicine at UCLA, founding director emeritus of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, and the UC Regents’ David Saxon Presidential Chair in developmental immunology (1989–present). Witte is also a Howard Hughes Medical Institute investigator (1986–2016) and a member of the President's Cancer Panel, the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the Cancer Research Academy of the AACR. He serves on numerous editorial boards and scientific advisory boards for academic centers and biotechnology companies.

Michael A. Caligiuri is an American physician scientist focused on oncology and immunology. He is currently the president of the City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. He was elected president of the American Association for Cancer Research, the world's largest cancer research organization, for 2017–2018. He was previously the CEO of the James Cancer Hospital (2008-2017), Director of the Comprehensive Cancer Center (2003-2017), and Director of the Division of Hematology-Oncology (2000-2008) at the Ohio State University. He was elected to the United States National Academy of Medicine in 2018.

<span class="mw-page-title-main">Carl H. June</span> American immunologist and oncologist

Carl H. June is an American immunologist and oncologist. He is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research on T cell therapies for the treatment of several forms of cancers. In 2020 he was elected to the American Philosophical Society.

Nancy E. Davidson is the executive director and president of Seattle Cancer Care Alliance, senior vice president, director of clinical oncology at Fred Hutchinson Cancer Research Center and head of the Division of Medical Oncology at the University of Washington School of Medicine. She focuses her research on breast cancer treatments and the genes that are mutated in various forms of breast cancer. She was president of American Association for Cancer Research from 2015 to 2016 and president of American Society of Clinical Oncology from 2007 to 2008.

<span class="mw-page-title-main">Elizabeth Jaffee</span> American oncologist

Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.

Joseph Rocco Bertino was an American researcher in the cancer pharmacology program at Rutgers Cancer Institute of New Jersey and professor of medicine and pharmacology at the Robert Wood Johnson Medical School in New Jersey. His research focused on the treatment of lymphoma.

Miram Merad is a French-Algerian professor in Cancer immunology and the Director of the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM) at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY. She is the corecipient of the 2018 William B. Coley Award for Distinguished Research in Basic Immunology and a member of the United States National Academy of Sciences and the National Academy of Medicine.

<span class="mw-page-title-main">Crystal Mackall</span> American physician and immunologist

Crystal L. Mackall is an American physician and immunologist. She is currently the Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine at Stanford University. She is the founding director of the Stanford Center for Cancer Cell Therapy.

Pamela Sumiko Ohashi, PhD, FRSC is a Canadian medical researcher. She is co-director of the Campbell Family Institute for Breast Cancer Research, director of the Cancer Immune Therapy Program at the Princess Margaret Cancer Centre and a professor at the University of Toronto.

<span class="mw-page-title-main">Uğur Şahin</span> German oncologist and immunologist (born 1965)

Uğur Şahin is a German and Turkish oncologist, immunologist, and entrepreneur. He is the founder and CEO of BioNTech, which developed one of the major vaccines against COVID-19. His main fields of research are cancer research and immunology.

Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.

James R. Downing is an American clinical executive. He is the president and chief executive officer of St. Jude Children's Research Hospital.

Antoni Ribas is a Spanish American physician–scientist. He is a Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA) and Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center. Ribas served as president of the American Association for Cancer Research (AACR) in 2021–2022.

Adekunle O. Odunsi is an American gynecologic oncologist. In 2021, Odunsi became the director of the University of Chicago Comprehensive Cancer Center.

Cornelis Joseph Maria Melief is a Dutch immunologuist specialising in cancer immunology and immunotherapy, with a focus on therapeutic cancer vaccines. He is emeritus Professor, former head of the Department of Immunohematology and Blood Transfusion at the Leiden University Medical Center, and Chief Scientific Officer at ISA Therapeutics in Netherlands. He is known for his work in the field of cancer immunology, devising new cancer therapies based on the activation of the patient's own immune system.

Lisa M. Coussens is an American cancer scientist who is Professor and Chair of the Department of Cell, Developmental and Cancer Biology and Deputy Director for Basic and Translational Research in the Knight Cancer Institute at the Oregon Health & Science University. She served as 2022-2023 President of the American Association for Cancer Research.

Lieping Chen is a Chinese-American immunologist and physician-scientist.

References

  1. "Dr. Phil Greenberg named 2018 Leader in Health Care". Fred Hutch. March 2, 2018.
  2. "A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies". STAT. January 13, 2022.
  3. "Leading cancer research centers team up to launch biotech startup focused on cancer immunotherapy". Fierce Biotech. December 4, 2013.
  4. Schubert, Charlotte (March 30, 2022). "Biotech vet Phil Greenberg on his new cancer-fighting startup and immunotherapy's next phase". GeekWire.
  5. "Philip – Greenberg – PMWC Precision Medicine World Conference". pmwcintl.com. Retrieved July 19, 2022.
  6. 1 2 "Philip Greenberg, MD, to Present the 2019 American Society of Hematology E. Donnall Thomas Lecture". www.hematology.org.
  7. Riddell, Stanley R.; Watanabe, Kathe S.; Goodrich, James M.; Li, Cheng R.; Agha, Mounzer E.; Greenberg, Philip D. (July 10, 1992). "Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones". Science. 257 (5067): 238–241. Bibcode:1992Sci...257..238R. doi:10.1126/science.1352912. PMID   1352912.
  8. Walter, Elizabeth A.; Greenberg, Philip D.; Gilbert, Mark J.; Finch, Rosalynde J.; Watanabe, Käthe S.; Thomas, E. Donnall; Riddell, Stanley R. (October 19, 1995). "Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor". New England Journal of Medicine. 333 (16): 1038–1044. doi: 10.1056/NEJM199510193331603 . PMID   7675046.
  9. "Spotlight on Phil Greenberg". Fred Hutch.
  10. 1 2 3 4 5 6 7 8 "Philip D. Greenberg, MD". American Association for Cancer Research. Retrieved December 21, 2023.
  11. "Greenberg receives immunotherapy award". fredhutch.org. September 26, 2011.
  12. "Good News at Fred Hutch". fredhutch.org. October 1, 2015.
  13. "Good News: Fred Hutch immunotherapy expert Dr. Phil Greenberg joins Parker Institute". November 30, 2017.
  14. "Dr. Philip Greenberg elected to serve on AACR board of directors". fredhutch.org. March 31, 2017.
  15. "Philip D. Greenberg, MD | SITC 2018 Keynote Speaker". sitcancer.org. Retrieved July 19, 2022.
  16. "Dr. Philip Greenberg elected a Distinguished Fellow of the American Association of Immunologists". fredhutch.org. April 19, 2019. Retrieved February 27, 2022.
  17. "Philip D. Greenberg, MD, FAACR, Elected as American Association for Cancer Research President-Elect for 2022–2023". American Association for Cancer Research. Retrieved December 21, 2023.
  18. "Society for Immunotherapy of Cancer (SITC) Announces Inaugural Class of Fellows to the Academy of Immuno-Oncology". www.sitcancer.org. Retrieved December 21, 2023.
  19. "American Association for Cancer Research Inaugurates New Leadership at the AACR Annual Business Meeting of Members 2023" . Retrieved May 17, 2023.
  20. Fronek, Laurie (May 11, 2023). "Dr. Philip Greenberg elected to National Academy of Sciences".